Akero Therapeutics Announces Two Financing Transactions With Pfizer Inc. And Hercules Capital, Inc. Providing Access To Up To $125 Million
Akero Therapeutics Announces Two Financing Transactions With Pfizer Inc. And Hercules Capital, Inc. Providing Access To Up To $125 Million
06/16/22, 7:00 AM
Location
san franciscoIndustry
therapeutics
biotechnology
health care
Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced two financing transactions. The first is a $25 million equity investment by Pfizer Inc. (NYSE: PFE) at $9.90 per share
Company Info
Location
san francisco, california, united states
Additional Info
Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, is currently being evaluated in a Phase 2b clinical trial as a potential treatment for NASH. Akero is headquartered in South San Francisco.